Newsroom & White Papers

News Featuring Boudicca Dx

Adial Pharma Developing Regulatory Strategy for CDx Genetic Test for Alcohol Use Disorder Drug

August 16, 2024Precision Medicine Online

Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04

August 13, 2024Adial Pharmaceuticals

Proteotype Welcomes Dr. Kelly Gordon to Scientific Advisory Board

June 1, 2024Proteotype Diagnostics

Dr. Kelly Gordon, Ph.D., MB (ASCP) joins Cellens Inc Scientific Advisory Board!

April 25, 2024Cellens Inc

Poster Presentation, 2024 Tandem Meetings Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. An AML targeted Duplex Sequencing assay can detect Measurable Residual Disease (MRD) at a sensitivity better than 0.01% Variant Allele Frequency

February 21, 2024TwinStrand Biosciences

Boudicca Dx White Papers

Proposed Framework for Leveraging a Distributed Pan-cancer Profiling IVD as a Companion Diagnostic for Oncology Targeted Molecular Therapies

Published online. September 9, 2024. Boudicca Dx., LLC All rights reserved.

Disclaimer: The opinions expressed in this white paper are solely those of Boudicca Dx., LLC and do not reflect those of any entity mentioned.